Atacicept (Vera): BAFF+APRIL Dual Inhibitor for IgAN Phase 3
Vera Atacicept: TACI-Fc BAFF+APRIL dual. ORIGIN Ph2b 36-wk UPCR -35% PBO-adj; ORIGIN 3 (NEJM 2026, n=203 interim) 41.8pp reduction. PDUFA Jul 7, 2026.
Introduction: Hitting B-Cell Cytokines from Both Sides
In IgAN, sibeprenlimab has reached FDA accelerated approval while zigakibart remains in Phase 3; against that APRIL-only backdrop, Vera Therapeutics' Atacicept, a TACI-Fc fusion protein that neutralizes both BAFF and APRIL, offers deeper upstream suppression of Gd-IgA1 production. ORIGIN Phase 2b (Lafayette R et al., Kidney Int 2024, n=116) showed 36-week UPCR placebo-adjusted −35%, and ORIGIN 3 Phase 3 (Lafayette R et al., NEJM 2026;394(7):647-657, full enrollment n=431 completed Apr 2025, prespecified interim n=203: atacicept 106 + placebo 97) reached a placebo-adjusted reduction of 41.8 percentage points, with a PDUFA target action date of July 7, 2026 under Priority Review (pending FDA approval)[1][2].
1. Compound Profile
| Item | Detail |
|---|---|
| Generic name | Atacicept |
| Origin | ZymoGenetics → Merck Serono (EMD Serono) → Vera Therapeutics (licensed from Merck KGaA, Nov 9, 2020) |
| Modality | TACI-Fc fusion (human TACI ectodomain + IgG1 Fc), BAFF + APRIL dual neutralization |
| Dose | 150 mg SC QW |
| Target approval | IgAN (ORIGIN Phase 3), PDUFA target Jul 2026 |
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. BAFF/APRIL Biology in IgAN
- APRIL: IgA plasma cell survival, IgA1 class switching, Gd-IgA1 overproduction driver
- BAFF: upstream B-cell survival, maturation, T-dependent antibody responses
- Dual inhibition rationale: captures BAFF-dependent B-cell compartments that escape APRIL-only blockade, adding depth to Gd-IgA1 suppression
- Trade-off: a broader immunologic effect than APRIL-only blockade may require longer-term monitoring of immunoglobulins (IgG/IgA/IgM), infections, and vaccine responses (in the ORIGIN 3 interim, Vera reported safety comparable to placebo)
3. Mechanism: Differentiation vs Sibeprenlimab
| Agent | Target | Immune breadth | Dosing |
|---|---|---|---|
| Atacicept | BAFF + APRIL dual (TACI-Fc) | Pan-B + plasma cells | SC QW |
| Povetacicept (Vertex / Alpine Immune Sciences) | BAFF + APRIL dual (engineered TACI-Fc, hi-affinity) | Same, deeper engagement | SC Q4W |
| Telitacicept (RemeGen) | BAFF + APRIL dual (TACI-Fc) | Same; approved in China for SLE/MG | SC QW |
| Sibeprenlimab | APRIL only | IgA plasma cells | SC Q4W |
| Zigakibart (BION-1301) | APRIL only (IgG4) | Similar | SC Q2W |
Clinical differentiation: Atacicept differentiates through dual BAFF/APRIL blockade with consistent Gd-IgA1, hematuria, and UPCR improvements, while sibeprenlimab differentiates through APRIL-only biology and Q4W dosing — efficacy and safety rankings are not established without head-to-head data. Within the BAFF+APRIL dual-blockade class, Povetacicept (Vertex acquired Alpine in 2024; RAINIER Phase 3, UPCR placebo-adjusted −49.8% at the 2026-03 interim, rolling BLA submission completed in March 2026, potential accelerated approval) is the closest competitor.
4. Clinical Evidence
4-1. ORIGIN Phase 2b[3]
- Design: IgAN, n=116, 150/75 mg SC QW vs placebo
- 24-week UPCR: placebo-adjusted −25% (atacicept −31% vs placebo −8%)
- 36-week UPCR: placebo-adjusted −35% (atacicept −34% vs placebo +2%, significant)
- 36-week eGFR: +5.7 mL/min/1.73m² stabilization vs placebo
- Gd-IgA1: significantly reduced
- Lafayette R et al., Kidney Int 2024;105(6):1306-1315 (PMID 38552841, Barratt J senior author)
4-2. ORIGIN 3 Phase 3 (NCT04716231)[1][2]
- Design: randomized DB placebo-controlled, IgAN, full enrollment n=431 (completed Apr 2025, Vera PR), prespecified interim n=203 (atacicept 106 + placebo 97; ClinicalTrials.gov listed estimated enrollment 376), 150 mg SC QW
- Primary: 36-week UPCR change (pre-specified interim, full analysis set)
- Interim (ASN Kidney Week 2025 / NEJM online 2025-11-06): atacicept UPCR −45.7% vs placebo −6.8%, between-group reduction of 41.8 percentage points (95% CI 28.9 to 52.3, p<0.001)
- Secondary: Gd-IgA1 −68%, hematuria resolved 81%, serious adverse events 0.5% vs 5% (atacicept vs placebo)
- eGFR slope: two-year (24-month) eGFR data expected Q1 2027 and central to full-approval conversion[7]
- BLA / Priority Review: filed under the Accelerated Approval Program; PDUFA target action date July 7, 2026 (pending FDA approval)[6]
- Lafayette R et al., N Engl J Med 2026;394(7):647-657 (PMID 41196369, online 2025-11-06, DOI 10.1056/NEJMoa2510198, Barratt J senior author)
4-3. PIONEER Phase 2 (FSGS / MCD)
- PIONEER Phase 2 basket (NCT06983028): expanded IgAN, anti-PLA2R-positive pMN, and anti-nephrin-positive FSGS / MCD — expansion to non-Gd-IgA1-driven glomerular diseases. Initial results are expected in Q2 2026; no results were found as of May 24, 2026[7].
5. Regulatory
- FDA Breakthrough Therapy Designation: granted May 28, 2024 (IgAN)
- FDA BLA: Q4 2025 filing via the Accelerated Approval Program under Priority Review, PDUFA target action date July 7, 2026 (pending FDA approval)[6]
- Full approval: gated on two-year eGFR slope data expected Q1 2027[7]
- EMA / PMDA: limited public information
6. SLE Failure → IgAN Pivot
- APRIL-SLE (2011-2015): SLE, flare reduction trend but primary EP missed; high-dose arm halted due to serious infections/deaths (Ann Rheum Dis 2015;74(11), PMID 24951103)
- Pivot rationale: well-defined BAFF/APRIL-Gd-IgA1 axis in IgAN, narrower renal-immune scope, optimized 150 mg QW dose
7. Competitive Landscape (IgAN)
| Agent | MoA | Phase | Primary EP |
|---|---|---|---|
| Atacicept | BAFF/APRIL dual | Phase 3 (ORIGIN 3), PDUFA Jul 7 2026 | UPCR 41.8pp PBO-adjusted reduction (interim n=203, full 431) |
| Povetacicept (Vertex / Alpine) | BAFF/APRIL dual (hi-affinity) | Phase 3 (RAINIER), rolling BLA completed Mar 2026 | UPCR −49.8% PBO-adj (2026-03 interim) |
| Telitacicept (RemeGen) | BAFF/APRIL dual | Approved in China (SLE/MG); TELIGAN China Ph3 interim, NEJM 2026 | 55.0% placebo-adjusted relative proteinuria reduction at Week 39 (baseline −58.9% vs PBO −8.8%), eGFR stable |
| Sibeprenlimab | anti-APRIL | FDA accelerated Nov 2025 | UPCR between-group −51.2% (sibeprenlimab −50.2% vs placebo +2.1%, 95% CI −58.2 to −42.9) |
| Zigakibart (BION-1301) | anti-APRIL | Phase 3 (BEYOND) | UPCR −60% (Ph1/2) |
| Iptacopan | Factor B | FDA Aug 2024 accelerated | UPCR −38.3% at 9 months (accelerated-approval basis) plus 24-month eGFR slope |
| Sparsentan | ETA/AT1R | Full approval | UPCR −50% |
| Atrasentan | ETA-selective | Accelerated Apr 2025 | UPCR −36.1% |
8. Preclinical & Biomarkers
- Serum BAFF / APRIL: direct response markers
- Gd-IgA1: disease biomarker, −60% in Atacicept arm
- Total IgG / IgA / IgM: hypogammaglobulinemia monitoring
- UPCR / eGFR slope: clinical endpoints
9. Points to Watch
- ORIGIN 24-month eGFR slope — gates full approval
- FDA approval timing (PDUFA Jul 2026, pending approval) — second FDA decision after sibeprenlimab; differentiated by dual BAFF/APRIL mechanism (no head-to-head data)
- PIONEER Phase 2 basket (expanded IgAN / anti-PLA2R+ pMN / anti-nephrin+ FSGS・MCD) — initial results expected Q2 2026 (not reported as of May 24, 2026)
- Head-to-head dynamics with Sibeprenlimab / Zigakibart
- Long-term infection risk from BAFF suppression — hypogammaglobulinemia management
References
1. Lafayette R, et al. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (ORIGIN 3). N Engl J Med. 2026;394(7):647-657. PubMed 41196369 / NEJM / ClinicalTrials.gov: NCT04716231
2. Vera Therapeutics. Positive ORIGIN Phase 3 Data for Atacicept in IgAN presented at ASN Kidney Week 2025 (Priority Review, PDUFA 2026-07-07). Press release, November 6, 2025. Vera IR
3. Lafayette R, et al. Efficacy and Safety of Atacicept in IgA Nephropathy (ORIGIN Phase 2b). Kidney Int. 2024;105(6):1306-1315. PubMed 38552841
4. Isenberg D, et al. Efficacy and safety of atacicept for prevention of flares in patients with SLE (APRIL-SLE). Ann Rheum Dis. 2015;74(11):2006-2015. PubMed 24951103
5. Vera Therapeutics. Atacicept PIONEER Phase 2 basket (expanded IgAN / anti-PLA2R+ pMN / anti-nephrin+ FSGS・MCD). ClinicalTrials.gov: NCT06983028
6. Vera Therapeutics. U.S. FDA Granted Priority Review to Atacicept BLA (PDUFA target action date July 7, 2026). Press release, January 7, 2026. Vera IR
7. Vera Therapeutics. Business Update and First Quarter 2026 Financial Results (PIONEER initial results Q2 2026; ORIGIN 3 two-year eGFR Q1 2027; commercial launch pending FDA approval). Press release, May 7, 2026. Vera IR